Friday, October 30, 2009

FAS vs FAZ 10/30/2009.. Whats Today?

FAZ Day might be started today... WATCH OUT BEAR......

Yesterday was the rally of the day, and Bull has run fast enough to recover from the complete damage to most of the portfolios.

Read more information:
http://www.reuters.com/article/BROKER/idUSLU25081620091030

Today the US Stocks Futures slightly dip in the opening, which indicates the BEAR is taking the control over bull, hence i would put on FAZ and short on FAS.

But watch out till opening of the day, because it is still a slight dip in us futures, so it can be mixture of bull and bear. And Asian Stocks rose few percent, and Still the Job Rate is getting released soon, that might pull down the rising percentage.

So watch out FAZ for quick run and there by quick profit in few hours.....


Again as i always say, do your DD, analysis, use your best judgments.

i do not recommend any stocks in this site, its my personal opinion.


Thursday, October 29, 2009

Alcoa - an Overview , exciting company to watch out for big break and good target price..

Alcoa company, the Stock Symbol "AA" - is the largest aluminium manufacturer and supplier of the United States of America.

Just want to give you all on developments going at Alcoa (AA).

Recently Alcoa (AA) announced the big profit announced third quarter 2009 income from continuing operations of $73 million, or $0.07 per diluted share, compared to a loss from continuing operations of $312 million, or $0.32 per share, in the second quarter 2009. Income from continuing operations in the third quarter of 2008 was $306 million, or $0.37 per share. Excluding restructuring and special items, income for the third quarter 2009 was $39 million, or $0.04 per share.

According to the industry analyst, this is a excellent result made by AA, and would drive the price target to $18.

And since the market correct happened this mid-week, and huge sell-off on the exchanges, the AA also get affected, lead to $11.83 from $15.

This week, Alcoa has made partnership with a Russian company to work with Nanotechnology based aluminium development and manufacturing. This is going to be huge welcoming point for Alcoa.

And Aloca signed on RUSNANO memorandum today, which is a major milestone in its developments. http://stocks.us.reuters.com/stocks/keyDevelopments.asp?rpc=66&symbol=AA×tamp=20091029200000

Alcoa is on its way to tieup with devleoping new jet reuters. Read more info
http://stocks.us.reuters.com/stocks/keyDevelopments.asp?rpc=66&symbol=AA×tamp=20091029100000

http://www.bloomberg.com/apps/news?pid=20601080&sid=argKLunM3Axs

Alcoa presented water technology at china america national symposium . Read more information at http://www.azom.com/news.asp?newsID=19446

Lot of developments by AA, and i believe this is good time to get in , and keep it for long, but as i always say, do your DD, and analysis, use your best judgement.

All the best!!


Best day in Three months, after the worst day in past 10 months

DOW went up and up, and this is the day best in past three months.

All the sectors got into recovery mode, after the GDP gets released this morning.

The FAS went up +7 and FAZ went down -2.5

Read more information :

http://businessweek.mobi/detail.jsp?key=80683&rc=to

http://www.benzinga.com/markets/32714/dow-had-its-best-day-in-three-months-fas-c-bac-slv-exk-ati-gna-wor


Saturday, October 24, 2009

EUA granted for Permivira vaccine.

Finally fda has granted the Emergency Use authorization for the swine flu vaccine Permivira.

http://www.reuters.com/article/pressRelease/idUS10540+24-Oct-2009+PRN20091024

We should see a good spike on BCRX in monday premarket.


Though EUA has been granted, it is only allowed to use against hospitalized patients.

I hope we can play for quick profit on monday mrng, currently BCRX@9.85. Entering below 10, would be right entry, and with target exit 11.00 with first half.

Let us look for the best.

Note: Target is around 12 to 15 as per the site http://stockstowatch.blogspot.com/2009/10/jines-report-biocryst-mass-awareness.html

and entry under $12 is good, as per above site, but i would suggest around 10 is good.

-------
This site does NOT make Buy / Sell recommendations.
---------


Thursday, October 22, 2009

Life vs Death situation: Does Primvira get more attention?

Vax crisis could spur swift peramivir approval

http://www.fiercevaccines.com/story/vax-crisis-could-spur-swift-peramivir-
approval/2009-10-22##ixzz0UgZ2thI8



BCRX - will it be a good stock to invest for short term profits?

Why H1N1 Vaccines are delayed? Should we blame eggs?

Read more information on :
http://www.msnbc.msn.com/id/33420826/ns/health-cold_and_flu/

Would this boost the interest on Primvira vaccine that attracted the US Health department, and FDA to give EAU anytime... This will be the way to be in safer-side if the Vaccine manufactured from Eggs, does not give desirable results after nov/dec, where the Flu in its peak state.

More information:
http://localtechwire.com/business/local_tech_wire/news/blogpost/6259758/


Wednesday, October 21, 2009

Biocryst Pharma - Strong Expectation from Investors

Two solid source of information:

1) US working to ready more flu drugs, Congress told

Read more information on Reuters: http://www.reuters.com/article/companyNews/idUKN2149356920091021?pageNumber=2&virtualBrandChannel=11564

2) BioCryst Receives Peramivir Request for Proposal From the U.S. Government

Read more informatino on this site:
hhttp://www.bio-medicine.org/medicine-news-1/biocryst-receives-peramivir-request-for-proposal-from-the-u-s--government-57737-1/


Snapshots:

ecause influenza viruses mutate so quickly, health officials are keen for new drugs and several are in the works.

Furthest along in the pipeline is Biocryst Pharmaceuticals Inc's (BCRX.O) and Shionogi & Co's (4507.T) peramivir.

BioCryst has said it was starting two late-stage trials testing the intravenous formulation of peramivir to treat hospitalized patients with serious influenza.

In 2007, BioCryst was awarded a $102.6 million, four-year contract from HHS to develop peramivir for the treatment of influenza. Last month it got another $77.2 million from the department to complete late-stage development.

"We are very encouraged by the results but the scientists will lead our recommendations in terms of getting that antiviral on the market," Sebelius said.